Table 3.
TKI | Axitinib (Rugo, 2005) | Tivozanib (Eskens et al., 2011) |
---|---|---|
Number patients | 36 | 41 |
Dose levels (mg) | Six: 10–30, 20, 2.0, 5.0, 15, 5.0 | Three: 1.0, 1.5, 2.0 |
Schedule | Continuous (daily, BID) | Intermittent (4/2 week schedule) |
Median age (range) | 57 (41–76) years | 56 (28–73) years |
TUMOR TYPES | ||
CR Ca | 0 | 10 |
Breast | 13 | 0 |
RCC | 6 | 9 |
Other | 17 | 22 |
Maximum tolerated dose | 5.0 mg BID daily | 1.5 mg daily day 1–28 |
Clinical responses: PR stable disease | 3 (2 RCC patients) NS | 1 (RCC patient) 55% |
BID, twice daily; mg, milligram; RCC, renal cell carcinoma; CR Ca, colorectal cancer; PR, partial response; NS, not stated.